Does Medicare cover PCSK9 inhibitors like Repatha and Praluent?

Answered by 12 licensed agents

Yes, Medicare covers PCSK9 inhibitors like Repatha (evolocumab) and Praluent (alirocumab) primarily through Medicare Part D or Medicare Advantage plans with prescription drug coverage.

đź’ˇ Coverage and Formularies

• High Adoption: Around 83% to 95% of Medicare Part D and Advantage plans cover Repatha, while Praluent is also widely included depending on the specific insurer's formulary.

• Tier Placement: Usually placed on Specialty Tiers (Tier 5), meaning cost-sharing is a percentage of the drug's cost rather than a flat copay.

• Out-of-Pocket Cap: Total yearly out-of-pocket spending for Part D drugs is capped at $2,100, which limits maximum yearly costs if you hit the threshold.

⚠️ Approval Requirements

• Prior Authorization: Nearly all covering plans require your doctor to submit proof of medical necessity before approval.

• Step Therapy: Insurers typically require documentation that you tried and failed or could not tolerate maximally dosed statins alongside other adjuncts like ezetimibe first.

Answered by Mark Boone on October 5, 2026

Agent Licensed in MN, FL, MI & NC, OH, SC & VA

Answered by Mark Boone Medicare Insurance Agent
Yes. Medicare can cover PCSK9 inhibitors such as Repatha and Praluent, but coverage depends on your specific Medicare drug plan.

Because Repatha and Praluent are medications you typically inject yourself, they are generally covered through Medicare Part D, rather than Part B. Medicare Part B mainly covers a limited group of medications that are given in a doctor's office or other outpatient medical setting.

The important part is that every Part D plan has its own formulary, or list of covered drugs. One plan may cover Repatha, another may prefer Praluent, and some plans may place additional requirements on coverage.

These medications may require prior authorization, step therapy, or documentation from your doctor showing why the medication is medically necessary. Medicare drug plans are allowed to use these coverage rules.

If your doctor prescribes Repatha or Praluent, check your exact Part D or Medicare Advantage drug formulary before assuming it is covered. If the prescribed medication is not covered, ask whether the plan prefers another PCSK9 inhibitor or whether your doctor can request a formulary exception.

So the short answer is yes, Medicare drug coverage may cover Repatha or Praluent, but you need to check the exact plan because coverage and approval requirements can vary.

Answered by Jeremy Harkins on September 25, 2026

Broker Licensed in TN, AR, CA & 5 other states

Answered by Jeremy Harkins Medicare Insurance Agent
Yes, Medicare can cover PCSK9 inhibitors such as Repatha and Praluent, but coverage depends on your specific Medicare Part D or Medicare Advantage prescription drug plan.

These medications are usually covered under Part D, and the insurance company may require prior authorization or other criteria before approving them. Coverage and out-of-pocket costs can vary considerably from one plan to another.

If you’re already taking Repatha or Praluent, or your doctor is considering prescribing one, I would recommend checking your specific plan’s formulary and coverage requirements before assuming it’s covered.

This is also why it’s so important to include all of your medications when comparing Medicare plans each year. The plan with the lowest monthly premium isn’t necessarily the plan that will cost you the least overall.

Answered by Cody Biggs on August 20, 2026

Broker Licensed in LA, AL, AZ & 24 other states

Answered by Cody Biggs Medicare Insurance Agent
Yes, Medicare covers PCSK9 inhibitors like Repatha and Praluent, but coverage is provided through private Medicare Part D prescription drug plans or Medicare Advantage plans with drug coverage (MAPDs) rather than Original Medicare Part B.

Approximately 90% to 95% of Medicare prescription plans include at least one PCSK9 inhibitor on their formulary, but getting approval and managing the costs requires navigating a few specific rules.

Answered by Christopher Horan on October 5, 2026

Agent Licensed in PA, DE, FL & NJ, NY, TX & VA

Answered by Christopher Horan Medicare Insurance Agent
Often, yes—through Medicare Part D, including a Part D plan bundled with Medicare Advantage. But coverage isn’t automatic: each plan has its own drug list and rules, and it may cover one of these medicines but not the other.

medicare.gov

Plans may require prior authorization or step therapy—for example, documentation of your diagnosis and that other cholesterol medicines were tried or weren’t suitable. Your cost depends on your plan’s formulary tier and pharmacy.

medicare.gov

To check, look up the exact medicine—Repatha (evolocumab) or Praluent (alirocumab)—in your plan’s formulary, or use Medicare’s Plan Finder. In 2026, your out-of-pocket spending on covered Part D drugs is capped at $2,100 for the year; that doesn’t guarantee coverage for a drug your plan excludes.

medicare.gov

If your plan denies coverage, you or your prescriber can request a coverage determination or an exception.

medicare.gov

Answered by John Hose on November 9, 2026

Broker Licensed in MD, FL, NC & 7 other states

Answered by John Hose Medicare Insurance Agent
Yes, Medicare does cover PCSK9 inhibitors like Repatha and Praluent, but only under Part D or a Medicare Advantage plan with drug coverage, and the plan has to list them on its formulary. Most plans require prior authorization, and your copay can vary a lot depending on the plan.

Answered by Corey Bennett on August 26, 2026

Broker Licensed in IN

Answered by Corey Bennett Medicare Insurance Agent
Yes, PCSK9 inhibitors can be covered by Medicare. However, they will be covered under the Part D portion of your Medicare as they are self-administered. Your actual coverage and cost will depend specifically on your plan's formulary. These drugs typically require prior authorization.

Answered by Mark Bilgere on August 26, 2026

Broker Licensed in TX, AR, IN & LA, MN, NE & OK

Answered by Mark Bilgere Medicare Insurance Agent
Yes, Medicare covers these; they are covered by Part D under specialty drugs, typically. May require step therapy and prior authorization to get these. For 2026, the max out of pocket for drugs is $2,100.

Answered by Kenneth Parsons on August 20, 2026

Agent Licensed in NM, AZ & TX

Answered by Kenneth Parsons Medicare Insurance Agent
Yes Medicare generally covers PCSK9 inhibitors such as Repatha and Praluent, but coverage depends on your specific Medicare Drug plan. These medications are typically covered under a Medicare Part D or a Medicare Advantage plan that includes drug coverage because they are self-administered injectable prescriptions.

Answered by Cynthia (Cindy) Dixon on October 26, 2026

Broker Licensed in AR, MO, MS, OK, TN & TX

Answered by Cynthia (Cindy) Dixon Medicare Insurance Agent
An independent check confirms Repatha is widely covered by Alabama Medicare Advantage and Prescription Drug Plans (PDPs). In contrast, only one standalone PDP in the state covers Praluent, demonstrating how coverage heavily depends on each insurance company's specific formulary (drug list).

Answered by Michelle Hylton on August 21, 2026

Broker Licensed in AL, CA, FL & 5 other states

Answered by Michelle Hylton Medicare Insurance Agent
Most Medicare prescription drug plans and Medicare Advantage plans with Prescription Drug coverage will cover these drugs, although you will want to check the plan you are considering to make sure this or any treatment you receive is covered and what will be your out-of-pocket costs.

Answered by Marcia West on August 18, 2026

Agent Licensed in WA, FL, GA, MI, TX & VA

Answered by Marcia West Medicare Insurance Agent
You need to check each plan's formulary. Then check the plans against each other for pricing. This is the only way to truly know if the drug is covered and what you will pay for it.

Answered by Michael Ferraro on October 5, 2026

Agent Licensed in NY

Answered by Michael Ferraro Medicare Insurance Agent

Tags: Coverage Medicare Part D Prescription Drug

Agents: Share Your Expertise

Have insights or experiences related to this topic? Help others by sharing your knowledge and answering this question.

Seniors: Ask a Question of Your Own

Questions are generally answered within 1 to 3 business days. Receive valuable perspectives from multiple licensed agents and brokers.

Ask a Question